Simplify Asset Management Inc. lifted its holdings in IQVIA Holdings Inc. (NYSE:IQV – Free Report) by 92.6% during the 4th quarter, HoldingsChannel.com reports. The firm owned 17,418 shares of the medical research company’s stock after acquiring an additional 8,374 shares during the quarter. Simplify Asset Management Inc.’s holdings in IQVIA were worth $3,926,000 at the end of the most recent reporting period.
Several other hedge funds also recently made changes to their positions in the business. Claret Asset Management Corp grew its stake in shares of IQVIA by 1.1% in the 3rd quarter. Claret Asset Management Corp now owns 4,527 shares of the medical research company’s stock worth $860,000 after purchasing an additional 49 shares during the last quarter. Leonard Rickey Investment Advisors P.L.L.C. grew its stake in shares of IQVIA by 3.3% in the 4th quarter. Leonard Rickey Investment Advisors P.L.L.C. now owns 1,814 shares of the medical research company’s stock worth $409,000 after purchasing an additional 58 shares during the last quarter. Brookstone Capital Management grew its stake in shares of IQVIA by 2.2% in the 4th quarter. Brookstone Capital Management now owns 2,931 shares of the medical research company’s stock worth $661,000 after purchasing an additional 63 shares during the last quarter. Private Advisor Group LLC grew its stake in shares of IQVIA by 1.0% in the 3rd quarter. Private Advisor Group LLC now owns 6,122 shares of the medical research company’s stock worth $1,163,000 after purchasing an additional 63 shares during the last quarter. Finally, Keybank National Association OH grew its stake in shares of IQVIA by 0.7% in the 4th quarter. Keybank National Association OH now owns 9,103 shares of the medical research company’s stock worth $2,052,000 after purchasing an additional 67 shares during the last quarter. Institutional investors and hedge funds own 89.62% of the company’s stock.
Analysts Set New Price Targets
Several brokerages have commented on IQV. Evercore reiterated an “outperform” rating and issued a $185.00 target price on shares of IQVIA in a report on Wednesday, April 8th. BMO Capital Markets set a $250.00 target price on shares of IQVIA in a report on Friday, February 6th. Morgan Stanley set a $225.00 target price on shares of IQVIA in a report on Thursday, May 7th. UBS Group decreased their target price on shares of IQVIA from $280.00 to $240.00 and set a “buy” rating for the company in a report on Friday, February 6th. Finally, JPMorgan Chase & Co. decreased their target price on shares of IQVIA from $255.00 to $225.00 and set an “overweight” rating for the company in a report on Friday, February 6th. Two equities research analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $225.69.
IQVIA Stock Performance
IQV stock opened at $168.28 on Monday. The company has a debt-to-equity ratio of 2.20, a quick ratio of 0.75 and a current ratio of 0.75. The stock has a market cap of $28.09 billion, a P/E ratio of 20.85, a P/E/G ratio of 1.61 and a beta of 1.18. The firm has a 50 day simple moving average of $169.72 and a 200 day simple moving average of $197.45. IQVIA Holdings Inc. has a 52 week low of $134.65 and a 52 week high of $247.04.
IQVIA (NYSE:IQV – Get Free Report) last posted its quarterly earnings results on Tuesday, May 5th. The medical research company reported $2.90 EPS for the quarter, topping the consensus estimate of $2.83 by $0.07. The business had revenue of $4.15 billion during the quarter, compared to analysts’ expectations of $4.10 billion. IQVIA had a net margin of 8.33% and a return on equity of 30.50%. The firm’s quarterly revenue was up 8.4% compared to the same quarter last year. During the same period last year, the company posted $2.70 earnings per share. IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. Research analysts anticipate that IQVIA Holdings Inc. will post 11.57 earnings per share for the current fiscal year.
IQVIA declared that its Board of Directors has authorized a stock repurchase plan on Thursday, May 7th that allows the company to buyback $2.00 billion in outstanding shares. This buyback authorization allows the medical research company to buy up to 6.8% of its shares through open market purchases. Shares buyback plans are typically an indication that the company’s board believes its shares are undervalued.
About IQVIA
IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.
IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.
See Also
- Five stocks we like better than IQVIA
- The Smart Glasses Gold Rush Is Leaving Old-School Eyewear Behind
- 3 Rare Earth Stocks That Win No Matter What China Does Next
- Amylyx Stock: Why the Full Pipeline Story Matters
- Palantir and Dell Build an AI OS for the Paranoid
Want to see what other hedge funds are holding IQV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IQVIA Holdings Inc. (NYSE:IQV – Free Report).
Receive News & Ratings for IQVIA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IQVIA and related companies with MarketBeat.com's FREE daily email newsletter.
